Stefanie M. Muller

Sankt Gallen, SG, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Journal: JAMA neurology

Published: August 03, 2026

Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.

Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: April 23, 2026

Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controls.

Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controls.

Journal: Clinical chemistry and laboratory medicine

Published: November 08, 2025

Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity.

Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: November 05, 2025

Use of optical coherence tomography in the care of people with multiple sclerosis in Switzerland: A national survey among neurologists.

Use of optical coherence tomography in the care of people with multiple sclerosis in Switzerland: A national survey among neurologists.

Journal: Multiple sclerosis journal - experimental, translational and clinical

Published: October 25, 2025

Unraveling Microstructural and Macrostructural Brain Age Dynamics in Multiple Sclerosis.

Unraveling Microstructural and Macrostructural Brain Age Dynamics in Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: August 19, 2025

Focus on MS - visual loss as a cardinal symptom of multiple sclerosis

Focus on MS - visual loss as a cardinal symptom of multiple sclerosis

Journal: Therapeutische Umschau. Revue therapeutique

Published: July 03, 2025

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

Journal: Brain : a journal of neurology

Published: June 14, 2025

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

Journal: Brain : a journal of neurology

Published: June 14, 2025

Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort.

Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort.

Journal: Journal of neurology

Published: May 05, 2025

Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study.

Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: April 29, 2025

Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response.

Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response.

Journal: Annals of clinical and translational neurology

Published: April 01, 2025

Showing 1-12 of 44

Last Updated: 09/26/2026